Theravance Biopharma (TBPH) Operating Expenses (2013 - 2026)

Theravance Biopharma (TBPH) has reported Operating Expenses for 14 consecutive years, with $27.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses fell 8.85% year-over-year to $27.2 million; the TTM figure through Mar 2026 stood at $108.4 million (down 6.08% YoY), while the FY2025 annual figure was $111.1 million, changed 0.24% from the prior year.
• Operating Expenses climbed to $27.2 million in Q1 2026 per TBPH's latest filing, from $25.9 million in the prior quarter.
• Across five years, Operating Expenses topped out at $51.7 million in Q1 2022 and bottomed at $21.6 million in Q3 2022.
• Historically, Operating Expenses has averaged $29.8 million across 5 years, with a median of $28.0 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Expenses sank 67.68% — and 2024, when it increased 17.43%.
• Theravance Biopharma's Operating Expenses stood at $32.1 million in 2022, then decreased by 25.8% to $23.8 million in 2023, then climbed by 17.43% to $28.0 million in 2024, then dropped by 7.42% to $25.9 million in 2025, then advanced by 5.03% to $27.2 million in 2026.
• Business Quant data shows TBPH's Operating Expenses at $27.2 million in Q1 2026, $25.9 million in Q4 2025, and $26.4 million in Q3 2025.